HRMY Hedge Fund Ownership (Q1 2026)

Harmony Biosciences Hldgs In (HRMY)

308 + Investors. Track Smart Money conviction in HRMY. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — HRMY

Based on 311 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q

For 1 consecutive quarter, more hedge funds reduced or closed their HRMY positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

🏔️

At the ownership peak (98% of max)

98% of all-time peak

311 hedge funds hold HRMY right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +19% more funds vs a year ago

fund count last 6Q

+50 new funds entered over the past year (+19% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟡

Slight buying edge — 55% buying

178 buying148 selling

Last quarter: 178 funds bought or added vs 148 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-15 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 42 → 47 → 59 → 44. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔒

52% of holders stayed for 2+ years

■ 52% conviction (2yr+) ■ 27% medium ■ 21% new

162 out of 311 hedge funds have held HRMY for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

💎

Buying through price weakness — shares +11%, value -24%

Value

-23%

+11%

Last quarter: funds added +11% more shares while total portfolio value only changed -24%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

41 → 42 → 47 → 59 → 44 new funds/Q

New funds entering each quarter: 42 → 47 → 59 → 44. A growing number of institutions are discovering HRMY each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🏛️

Veteran-anchored — 59% veterans vs 29% newcomers

■ 59% veterans ■ 12% 1-2yr ■ 29% new

Entry-cohort mix of 318 holders: 189 (59%) are 2+ year veterans, 38 entered 1–2 years ago, and 91 (29%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 60% AUM from top-100 funds

60% from top-100 AUM funds

53 of 309 holders are among the 100 largest funds by AUM, controlling 60% of total institutional value in HRMY. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.7

out of 10

Low Exit Risk

Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	308	317	-2.84%
13F Shares	56M	50M	10.89%
Total Value	$1.43B	$1.87B	-23.6%
New Positions	43	59	-16
Increased Positions	131	117	+14
Closed Positions	52	36	+16
Reduced Positions	95	109	-14
Total Calls	4	4	-
Total Puts	5	3	66.67%
PUT/CALL Ratio	1.25	0.75	Bearish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

308

317

-2.84%

13F Shares

56M

50M

10.89%

Total Value

$1.43B

$1.87B

-23.6%

New Positions

-16

Increased Positions

131

117

+14

Closed Positions

+16

Reduced Positions

109

-14

Total Calls

Total Puts

66.67%

PUT/CALL Ratio

1.25

0.75

Bearish

Institutional Holders (2026 Q2)

308 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in HRMY. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 HRMY holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Timothy G. Youngquist 2020 Irrevocable Trust	3.45%	125,918	$4.7M
2	venBio Partners LLC	3.31%	472,194	$17.2M
3	Tieton Capital Management, LLC	3.21%	306,781	$11.2M
4	Pavaki Capital Management LLC	1.92%	73,000	$2.7M
5	Sidoxia Capital Management, LLC	1.88%	70,629	$2.6M
6	Bridge City Capital, LLC	1.74%	209,200	$7.6M
7	Capital Management Corp /Va	1.56%	285,500	$10.4M
8	Aurora Investment Counsel	1.22%	65,148	$2.4M
9	Tetragon Partners GP Ltd	1.15%	201,036	$7.3M
10	Sphera Funds Management LTD.	0.84%	176,663	$6.4M
11	Nan Fung Group Holdings Ltd	0.75%	27,049	$985K
12	Armistice Capital, LLC	0.70%	1,564,000	$56.9M
13	Clark Estates Inc/Ny	0.68%	81,300	$3.0M
14	Quantedge Capital Pte Ltd	0.66%	24,000	$874K
15	Illumine Investment Management, LLC	0.60%	—	$929K
16	683 Capital Management, LLC	0.53%	294,000	$10.7M
17	Virtus Advisers, LLC	0.41%	29,253	$1.1M
18	Denali Advisors LLC	0.33%	89,600	$3.3M
19	Hedeker Wealth, LLC	0.32%	46,257	$1.7M
20	Paradiem, LLC	0.32%	40,854	$1.5M
21	Verdad Advisers, LP	0.30%	8,604	$313K
22	Virtus Investment Advisers, LLC	0.29%	33,746	$1.2M
23	City Center Advisors, LLC	0.28%	9,625	$350K
24	Yelin Lapidot Holdings Management Ltd.	0.25%	35,887	$1.3M
25	Zuckerman Investment Group, LLC	0.24%	78,255	$2.8M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Harmony Biosciences Hldgs In (HRMY)

What does the Smart Money Trend signal show for HRMY?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their HRMY positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for HRMY?

Slight buying edge — 55% buying: Last quarter: 178 funds bought or added vs 148 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for HRMY holders?

Elite ownership — 60% AUM from top-100 funds: 53 of 309 holders are among the 100 largest funds by AUM, controlling 60% of total institutional value in HRMY. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held HRMY?

52% of holders stayed for 2+ years: 162 out of 311 hedge funds have held HRMY for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Harmony Biosciences Hldgs In (HRMY)

Smart Money Signals — HRMY

Selling streak — 1 quarter in a row

At the ownership peak (98% of max)

Steady growth — +19% more funds vs a year ago

Slight buying edge — 55% buying

Fewer new buyers each quarter (-15 vs last Q)

52% of holders stayed for 2+ years

Buying through price weakness — shares +11%, value -24%

Growing discovery — still being found

Veteran-anchored — 59% veterans vs 29% newcomers

Elite ownership — 60% AUM from top-100 funds

Institutional Sentiment Summary — HRMY

Hedge Fund Ownership: HRMY

Market Analysis: HRMY

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: HRMY

Hedge Fund Positioning: HRMY

Statistics: HRMY

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Harmony Biosciences Hldgs In (HRMY)

Welcome to 13Foresight!